Coherus BioSciences, Inc.

NasdaqGM:CHRS Voorraadrapport

Marktkapitalisatie: US$123.3m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Coherus BioSciences Beheer

Beheer criteriumcontroles 3/4

De CEO Coherus BioSciences' is Denny Lanfear, benoemd in Sep2010, heeft een ambtstermijn van 14.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.90M, bestaande uit 16.7% salaris en 83.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.99% van de aandelen van het bedrijf, ter waarde $ 1.19M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.7 jaar en 3.3 jaar.

Belangrijke informatie

Denny Lanfear

Algemeen directeur

US$5.9m

Totale compensatie

Percentage CEO-salaris16.7%
Dienstverband CEO14.1yrs
Eigendom CEO1.0%
Management gemiddelde ambtstermijn2.7yrs
Gemiddelde ambtstermijn bestuur3.3yrs

Recente managementupdates

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Recent updates

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Sep 22
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 13

Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Aug 07
Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 31

Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

May 23
Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

Mar 21

Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Feb 03
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive

Coherus BioSciences: FDA Approvals Spice Up The Pipeline

Jan 17

Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

Dec 20
Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues

The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

May 13
The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically

Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3

Sep 19

Coherus: 2022 Is In Many Ways A Make Or Break Year

Aug 24

Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli

Aug 03

Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer

Jul 06

Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Jun 15
Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?

Coherus: Will Its Chinese Gambit Fail?

May 27

Analyse CEO-vergoeding

Hoe is Denny Lanfear's beloning veranderd ten opzichte van Coherus BioSciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$29m

Mar 31 2024n/an/a

-US$59m

Dec 31 2023US$6mUS$983k

-US$238m

Sep 30 2023n/an/a

-US$217m

Jun 30 2023n/an/a

-US$264m

Mar 31 2023n/an/a

-US$271m

Dec 31 2022US$7mUS$945k

-US$292m

Sep 30 2022n/an/a

-US$279m

Jun 30 2022n/an/a

-US$230m

Mar 31 2022n/an/a

-US$210m

Dec 31 2021US$9mUS$885k

-US$287m

Sep 30 2021n/an/a

-US$232m

Jun 30 2021n/an/a

-US$165m

Mar 31 2021n/an/a

-US$76m

Dec 31 2020US$7mUS$857k

US$132m

Sep 30 2020n/an/a

US$162m

Jun 30 2020n/an/a

US$181m

Mar 31 2020n/an/a

US$145m

Dec 31 2019US$5mUS$751k

US$90m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$118m

Mar 31 2019n/an/a

-US$185m

Dec 31 2018US$4mUS$702k

-US$209m

Sep 30 2018n/an/a

-US$196m

Jun 30 2018n/an/a

-US$196m

Mar 31 2018n/an/a

-US$208m

Dec 31 2017US$3mUS$656k

-US$238m

Compensatie versus markt: De totale vergoeding ($USD 5.90M ) Denny } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Denny is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Denny Lanfear (69 yo)

14.1yrs

Tenure

US$5,897,924

Compensatie

Mr. Dennis M. Lanfear, also known as Denny, Co-founder, Chairman, Chief Executive Officer and President of Coherus Biosciences Inc. since September 2010. Mr. Lanfear serves as the President of Lanfear Capi...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Dennis Lanfear
Chairman14.1yrsUS$5.90m0.99%
$ 1.2m
Bryan McMichael
Former Interim CFO2.1yrsUS$1.07m0.023%
$ 28.2k
Paul Reider
Chief Commercial Officer3.8yrsUS$1.93m0.071%
$ 87.0k
Richard Hameister
Chief Technical Officer2.8yrsgeen gegevensgeen gegevens
Jami Taylor
Vice President of Investor Relationsno datageen gegevensgeen gegevens
Andy Rittenberg
Executive Vice President of General Counselless than a yeargeen gegevensgeen gegevens
Cheston Turbyfill
Vice President of Communicationsno datageen gegevensgeen gegevens
Scott Saywell
Executive Vice President of Corporate Development1.8yrsgeen gegevensgeen gegevens
Rebecca Sunshine
Chief Human Resources Officerno datageen gegevensgeen gegevens
Michael Chen
Senior Vice President of Commercial Analytics & Tradeno datageen gegevensgeen gegevens
Theresa Lavallee
Chief Development Officer & Chairman of Scientific Advisory Board2.8yrsgeen gegevensgeen gegevens
Rosh Dias
Chief Medical Officer2.6yrsgeen gegevensgeen gegevens

2.7yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CHRS wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Dennis Lanfear
Chairman14.1yrsUS$5.90m0.99%
$ 1.2m
Theresa Lavallee
Chief Development Officer & Chairman of Scientific Advisory Board2.8yrsgeen gegevensgeen gegevens
Mats Wahlstrom
Lead Independent Director12.8yrsUS$228.69k0.087%
$ 107.0k
Mark Stolper
Independent Director3.8yrsUS$198.69k0.0076%
$ 9.4k
Ali Satvat
Independent Director10.4yrsUS$65.00k0%
$ 0
Lee Newcomer
Independent Director2.7yrsUS$186.19k0%
$ 0
James Daly
Member of Strategic Advisory Board1.1yrsgeen gegevensgeen gegevens
Charles Newton
Independent Director2.4yrsUS$188.69k0%
$ 0
Jill O'Donnell-Tormey
Independent Director2.4yrsUS$183.69k0%
$ 0
Kimberly Tzoumakas
Independent Director4.3yrsUS$193.69k0%
$ 0
Carl Ware
Member of Scientific Advisory Board3.3yrsgeen gegevensgeen gegevens
Thomas Graeber
Member of Scientific Advisory Board3.3yrsgeen gegevensgeen gegevens

3.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CHRS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).